Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04096950 · ClinicalTrials.gov registry record · Phase 1
Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury
A Phase 1 study, sponsored by Tanabe Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT04096950 is a Phase 1 study that has completed, run by Tanabe Pharma America. The registered enrollment target is 3 participants.
The verdict
NCT04096950, a Phase 1 study, has completed, sponsored by Tanabe Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability and pharmacokinetics of MT-3921 in subjects with spinal cord injury.
Interventions
- BIOLOGICAL MT-3921 Low dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-04-19 |
| Est. Completion | 2021-01-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04096950
The ClinicalTrials.gov registry entry for NCT04096950 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tanabe Pharma America, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MT-3921 Low dose is the first listed.
NCT04096950 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04096950 about?
NCT04096950 is a clinical study titled "Safety and Pharmacokinetics Study of MT-3921 in Spinal Cord Injury". The purpose of this study is to assess the safety, tolerability and pharmacokinetics of MT-3921 in subjects with spinal cord injury.
What is the current status of trial NCT04096950?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2020-04-19. Estimated completion is 2021-01-06.
What interventions are being tested in trial NCT04096950?
The interventions under investigation include: MT-3921 Low dose (BIOLOGICAL).
Who is sponsoring clinical trial NCT04096950?
This trial is sponsored by Tanabe Pharma America, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.